Want to see APVO full AI Analyst Report?
Top Page
Aptevo Therapeutics
(NASDAQ:APVO)
Select Model
Select Model
Rating:44Neutral
Price Target:
$4.50
▲(637.70% Upside)
Action:Reiterated
Date:07/10/26
The score is held down primarily by weak financial performance (no recurring revenue, large ongoing losses, and heavy negative free cash flow implying continued financing risk). Technicals also remain bearish with the stock below major moving averages and negative MACD, despite an oversold RSI. Positive corporate developments (trial data, collaboration, and non-dilutive grant funding) provide some offset, but not enough to overcome the current fundamentals and trend.
Positive Factors
Strong Phase 1b AML clinical data
RAINIER Phase 1b results showing very high response and remission rates materially de-risk mipletamig by evidencing deep, durable responses and a clean safety profile in frontline AML. Such durable clinical signals improve program credibility, accelerate dose selection and strengthen partner/commercial prospects over the medium term.
Negative Factors
High and persistent cash burn
Consistently large negative operating and free cash flows (~-$27M TTM) indicate structural cash burn that will require repeated external financing. This ongoing outflow constrains the firm's ability to internally fund multiple programs, increases execution risk, and raises the probability of dilutive capital raises over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Phase 1b AML clinical data
RAINIER Phase 1b results showing very high response and remission rates materially de-risk mipletamig by evidencing deep, durable responses and a clean safety profile in frontline AML. Such durable clinical signals improve program credibility, accelerate dose selection and strengthen partner/commercial prospects over the medium term.
Read all positive factors
Aptevo Therapeutics (APVO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$5.93M
Dividend YieldN/A
Average Volume (3M)11.64M
Price to Earnings (P/E)―
Beta (1Y)-0.16
Revenue GrowthN/A
EPS Growth99.36%
CountryUS
Employees33
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-357.16
Shares Outstanding1,246,105
10 Day Avg. Volume7,942,705
30 Day Avg. Volume11,635,265
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$21.00Price Target Upside3342.62% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-24.13
Revenue Forecast (FY)N/A
Aptevo Therapeutics Business Overview & Revenue Model
Company Description
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company primarily focused on pioneering immunotherapeutic agents for a variety of cancer treatments across the United States. Its foremost investigational drug, APVO436, is a bispecific an...
How the Company Makes Money
Aptevo’s revenue model is primarily partnership- and collaboration-driven, which is typical for clinical-stage biotechnology companies without a broad portfolio of marketed products. When it enters licensing or collaboration agreements, it can gen...
Aptevo Therapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
38
Negative
Cash Flow
10
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 3.11M | 12.29M |
| Gross Profit | -116.00K | -240.00K | -352.00K | 0.00 | 3.11M | 12.29M |
| EBITDA | -26.04M | -25.73M | -23.78M | -18.08M | 7.92M | -28.26M |
| Net Income | -26.26M | -25.97M | -24.13M | -17.41M | 8.03M | -28.46M |
Balance Sheet | ||||||
| Total Assets | 19.90M | 27.19M | 15.59M | 24.84M | 34.22M | 56.60M |
| Cash, Cash Equivalents and Short-Term Investments | 14.53M | 21.62M | 8.71M | 16.90M | 22.64M | 45.04M |
| Total Debt | 4.42M | 4.63M | 4.63M | 5.40M | 9.54M | 16.71M |
| Total Liabilities | 8.29M | 9.81M | 10.84M | 12.62M | 16.24M | 55.38M |
| Stockholders Equity | 11.61M | 17.38M | 4.75M | 12.22M | 17.97M | 1.22M |
Cash Flow | ||||||
| Free Cash Flow | -26.98M | -25.59M | -23.79M | -11.73M | -21.05M | -22.39M |
| Operating Cash Flow | -26.98M | -25.59M | -23.79M | -11.73M | -21.02M | -21.68M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | -29.00K | -713.00K |
| Financing Cash Flow | 39.37M | 38.50M | 15.60M | 6.00M | -2.62M | 26.16M |
Aptevo Therapeutics Technical Analysis
Negative
0.61
Price Trends
4.69
Negative
4.87
Negative
11.37
Negative
Market Momentum
-0.05
Negative
46.49
Neutral
78.69
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For APVO, the sentiment is Negative. The current price of 0.61 is below the 20-day moving average (MA) of 4.48, below the 50-day MA of 4.69, and below the 200-day MA of 11.37, indicating a bearish trend. The MACD of -0.05 indicates Negative momentum. The RSI at 46.49 is Neutral, neither overbought nor oversold. The STOCH value of 78.69 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for APVO.
Aptevo Therapeutics Risk Analysis
Aptevo Therapeutics disclosed 57 risk factors in its most recent earnings report. Aptevo Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Aptevo Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $11.42M | -0.08 | ― | ― | ― | 80.65% | |
47 Neutral | $56.07M | -4.34 | -82.34% | ― | ― | 16.07% | |
44 Neutral | $5.93M | -0.01 | -389.34% | ― | ― | 99.36% | |
43 Neutral | $18.62M | -1.63 | -112.05% | ― | ― | 94.17% | |
42 Neutral | $32.10M | -1.90 | -101.90% | ― | -83.00% | 19.02% |
* Healthcare Sector Average
APVO
Aptevo Therapeutics
4.42
-51.92
-92.15%
LSTA
Lisata Therapeutics
2.24
-0.40
-15.15%
MBRX
Moleculin Biotech
2.15
-17.24
-88.91%
EDSA
Edesa Biotech
6.03
3.60
148.15%
ALLR
Allarity Therapeutics
1.22
0.23
23.23%
Aptevo Therapeutics Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Aptevo Therapeutics Secures Grant for APVO451 Development
Positive
Jun 30, 2026
On June 29, 2026, Aptevo Therapeutics entered a Grant Award Agreement with the Andy Hill Cancer Research Endowment Fund, securing approximately $1.5 million in non-dilutive, reimbursement-based funding to support IND-enabling studies for APVO451, ...
Business Operations and StrategyPrivate Placements and Financing
Aptevo Forms Strategic Radiopharmaceutical Collaboration with Niowave
Positive
May 27, 2026
On May 25, 2026, Aptevo Research and Development LLC, a subsidiary of Aptevo Therapeutics, and Niowave entered into a 50/50 strategic collaboration to develop up to three radiopharmaceutical oncology programs combining Aptevo’s multispecific...
Business Operations and Strategy
Aptevo Highlights Strong Phase 1b AML Trial Results
Positive
May 6, 2026
On May 6, 2026, Aptevo reported new data from its RAINIER Phase 1b frontline acute myeloid leukemia trial showing that mipletamig, combined with venetoclax and azacitidine, achieved an 87% clinical benefit rate and 81% remission in 31 evaluable pa...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.